We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Method Directly Identifies Antigens

By LabMedica International staff writers
Posted on 23 Apr 2012
A novel method for identifying antigens is based on the isolation of T cells present in samples of affected tissues obtained from patients with autoimmune diseases. More...


The genetic blueprints for the specific antigen-binding T-cell receptors (TCRs) produced by these cells, have been transferred into a cultured cell line that grows well in the laboratory and contains a version of the gene for the Green Fluorescent Protein (GFP) that is specifically expressed if a TCR is activated.

Scientists at the Ludwig Maximilians University (Munich, Germany) collaborated with a team from the Max Planck Institute for Neurobiology (Munich, Germany) to develop the new method that can identify the antigens that initiate immune reactions and may help to prevent misdirected attacks in the future. They used genetic engineering techniques, to generate cells that emit green fluorescent light when stimulated by the binding of a cognate antigen.

The T-cells are incubated with a collection of some 100 million peptides, which are short amino acid sequences like those normally recognized by TCRs. If even a single peptide represented in the library is recognized by a specific TCR, the corresponding cell synthesizes GFP and it can be detected by its green fluorescence, allowing the bound antigen to be identified. The method thus provides a relatively simple way of identifying single autoimmune antigens from huge numbers of possible suspects.

An initial test carried out using cells specific for a known influenza antigen confirmed the efficacy of the method. The investigators were able unequivocally to select out and identify the correct antigen from all the other peptides used in the test. The technique is so rapid and so sensitive that several million antigens can be analyzed in a matter of hours. This opens up a wide range of possible applications, ranging from the analysis of the reactive antigens responsible for autoimmune diseases like multiple sclerosis or psoriasis to the identification of new tumor or viral antigens. The practical potential is so significant that the method is the subject of a patent application. The study was published online on April 8, 2012, in the journal Nature Medicine.

Related Links:

Ludwig Maximilians University
Max Planck Institute for Neurobiology



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.